These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 15520211)

  • 1. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
    Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
    Saha A; Chatterjee SK
    Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
    Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
    Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
    Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
    Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.
    Sfondrini L; Rodolfo M; Singh M; Colombo MP; Colnaghi MI; Ménard S; Balsari A
    Cancer Res; 2000 Jul; 60(14):3777-81. PubMed ID: 10919650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
    Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
    Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
    Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.